Prevalence of Persistent COVID-19 in Punta Arenas, Magallanes and Chilean Antarctic Region

Last updated: June 17, 2024
Sponsor: Universidad de Magallanes
Overall Status: Active - Recruiting

Phase

N/A

Condition

Covid-19

Treatment

Persistent COVID-19

Clinical Study ID

NCT05855382
FIC-R 40036196-0
  • Ages 18-100
  • All Genders

Study Summary

This cross-sectional observational study aims to determine the prevalence of Persistent COVID-19 in 282 individuals in Punta Arenas, Magallanes and Chilean Antarctic Region. Persistent COVID-19 is a complex array of symptoms that persist or emerge for more than 4 weeks beyond SARS-CoV-2 infection. Recent studies suggest that up to 80% of survivors may develop chronic multi-organ dysfunction due to persistent inflammation and immune dysregulation, making it an ongoing public health concern worldwide.

The study aims to (1) describe and establish the frequency of physical and psychological signs and symptoms in adult patients who have tested positive for COVID-19, (2) identify individuals who meet the WHO case definition of Persistent COVID-19 in Chile, (3) explore risk factors associated with persistent COVID-19 to guide intervention strategies, and (4) explore inflammatory and molecular biomarkers associated with persistent COVID-19.

The research project utilizes a stratified random sampling with a mixed-methods embedded design. In the first phase, individuals diagnosed with COVID-19 will be recruited and followed up to complete the study's sample universe. A sociodemographic survey, blood sampling (including complete blood count, biochemical profile, immunoglobulin mutational status analysis, and analysis of inflammatory biomarkers), and a battery of psychological tests will be administered. In the second phase, kinesiology studies and medical consultation and evaluation will be conducted to determine if individuals have Persistent COVID-19 and to derive them to the healthcare network. In the final follow-up phase, participants diagnosed with Persistent COVID-19 will be invited to undergo musculoskeletal and respiratory assessments to complete the diagnosis of symptoms associated with the pathology.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18 years

  • Individuals must be included in the COVID-19 monitoring database by the SEREMI ofHealth in Punta Arenas between July 2022 and July 2023.

  • Patients able to give informed consent.

Exclusion

Exclusion Criteria:

  • Age < 18 years

  • Any physical, mental, immunosuppressive, or social condition that, in theinvestigator's judgment, might interfere with the completion of the baselineassessments and evaluations.

  • Individuals who are digitally illiterate and do not have access to nearby networksto support them during the process.

Study Design

Total Participants: 282
Treatment Group(s): 1
Primary Treatment: Persistent COVID-19
Phase:
Study Start date:
May 15, 2023
Estimated Completion Date:
January 15, 2025

Connect with a study center

  • Teaching and Research Healthcare Center of the University of Magallanes (CADI-UMAG)

    Punta Arenas, Magllanes And Chilean Antartic Region 6200000
    Chile

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.